drugset / Trial / NCT04852523
18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
NaSingle-groupOpen-labelDiagnostic
Summary
Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its viability and visibility Hypothesis 2: 18F-Fluciclovine PET/CT uptake in the pancreas (SUV) is related to total pancreatic function and therefore can indicate whether the pancreatic allograft is at risk of rejection Aim 2: Assess whether 18F-Fluciclovine uptake in the pancreas can be a surrogate for pancreatic function
Timeline
- Start
- 2021-09-16
- Primary completion
- 2022-10-06
- Completion
- 2022-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-fluciclovine | Diagnostic / imaging agent | — | — |